Incyte and Iconix Collaborate on Chemogenomic Product | GenomeWeb

NEW YORK, May 30 – Incyte Genomics and Iconix Pharmaceuticals announced on Wednesday a collaboration to develop and commercialize the next-generation of Iconix’s ChemExpress chemogenomic platform.

Incyte will exclusively market and sell ChemExpress, according to the companies. Iconix will integrate Incyte’s LifeExpress Lead databases into ChemExpress under an exclusive license from Incyte, the companies announced. Under the terms of the agreement, Incyte will make an equity investment in Iconix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.